Preview: New evidence challenges DOAC interchangeability for VTE care
When it comes to treating venous thromboembolism (VTE), I’ve often heard apixaban and rivaroxaban described as “essentially the same”, just two options in the same class, offering similar outcomes. For a long time, that’s been the practical approach: choose whichever fits the patient’s lifestyle or insurance, and move on.
But a recent randomized trial is quietly upending that sense of equivalence, and I think it’s worth pausing to talk about why.
What the study set out to answer
The researchers conducted a multicenter, randomized study across 32 clinical sites, enrolling 2,760 patients with acute VTE. Their focus was specific and practical: when you treat VTE, does apixaban or rivaroxaban cause fewer clinically significant bleeding complications?
They tracked clinically relevant bleeding during the initial treatment phase, arguably the most anxiety inducing period for both clinicians and patients.
The results that matter
Here’s where it gets interesting. The findings showed a noticeable safety difference:
- Rivaroxaban: 7.1% of patients had a clinically relevant bleeding event.
- Apixaban: Only 3.3% experienced similar bleeding.
Both groups had similar rates of recurrent clotting events. So, while efficacy was comparable, the risk of bleeding wasn’t.
Let’s sit with that for a second. As clinicians, we like our medications organized into neat classes, with clear rules of thumb. But this study is a reminder that class doesn’t always equal clone. Two drugs, same family, but a meaningful gap in safety.
A common misunderstanding
Many of us reach for a DOAC and think, “Any of these will work just as well, right?” After all, both apixaban and rivaroxaban are direct oral anticoagulants, widely studied, widely used.
But these results make it clear: Drug-specific differences can matter even within the same class. Interchangeability is more convenient than it is accurate.
What this means for everyday practice
Clinical guidelines haven’t caught up to this head-to-head evidence yet. But as someone dedicated to evidence based care, I find myself rethinking old habits, especially for patients with a higher risk of bleeding.
- If both medications are reasonable, why not start with the one with a lower bleeding risk?
- How might this data shape your next discussion with a patient or colleague?
Sometimes, the biggest shifts in medicine don’t start with a guideline revision. They start with quiet, thoughtful decisions at the bedside, one clinician at a time, choosing differently because the evidence speaks.
A call to thoughtful action
If you’re treating VTE, it’s time to look beyond the class and consider the drug. It’s not about chasing trends; it’s about making choices grounded in the latest data, with patient safety front and center.
What will you do with this knowledge? Will you share it with your team? Will you ask different questions during your next case discussion?
Let’s keep challenging our assumptions, because our patients deserve that level of care and curiosity.
Sources: NEJM randomized VTE study summary; MUHC News coverage (2026).